Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L randomized clinical trial
复制标题
DOI：
10.1111/dom.14005
复制
发表时间：
2020-09-01
影响因子：
5.8
通讯作者：
Niemoeller, Elisabeth
中科院分区：
文献类型：
--
作者：
Kaneto, Hideaki;Takami, Akane;Niemoeller, Elisabeth
目的是在基础胰岛素和口服降糖药（OAD）控制不佳的2型糖尿病（T2DM）日本患者中评估甘精胰岛素和利司那肽固定比例（1：1）复方制剂（iGlarLixi）与甘精胰岛素U100（iGlar）联合二甲双胍相比的疗效和安全性。材料和方法这项为期26周的随机、开放标签研究比较了iGlarLixi与iGlar，两种药物均与二甲双胍联合治疗血红蛋白（Hb）A1c >= 7.5%的日本成年T2DM患者，
Aims To assess efficacy and safety of fixed-ratio (1:1) combination insulin glargine and lixisenatide (iGlarLixi) compared to insulin glargine U100 (iGlar), with metformin, in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled on basal insulin and oral antidiabetic drugs (OADs). Materials and methods This 26-week, randomized, open-label study compared iGlarLixi to iGlar, both with metformin in adult Japanese patients with T2DM and hemoglobin (Hb) A1c >= 7.5% to